BONESUPPORT has extended the term of its U.S. distribution agreement with Zimmer Biomet, where Zimmer will continue to have exclusive rights for BONESUPPORT’s cerament bone void filler product line for Orthopedics, Trauma and Foot and Ankle indications in the United States.
“We are extremely pleased to extend our distribution agreement with Zimmer Biomet,” said Richard Davies, CEO of BONESUPPORT. “The partnership has been very successful and has resulted in the current rapid growth of our flagship product, CERAMENT in the world’s largest bone graft substitute market. This rapid growth is building an important platform from which we can launch product extensions into the US.”
In addition to commercialization of cerament bone void filler in the U.S. market, BONESUPPORT is currently enrolling patients into the FORTIFY Clinical Study, an FDA approved IDE randomized control pivotal study for the company’s antibiotic eluting product cerament g. It is currently approved and commercialized in the EU and other markets outside the United States.
